$NUVL News

Wedbush Reiterates Outperform on Nuvalent, Maintains $125 Price Target

Nuvalent Announces Acceptance Of Its NDA For Neladalkib For Filing By FDA, With PDUFA Target Action Date Of November 27

Bernstein Initiates Coverage On Nuvalent with Outperform Rating, Announces Price Target of $189

Nuvalent To Present Pivotal ALKOVE-1 Data For Neladalkib In TKI-Pretreated ALK-Positive NSCLC And Early ARROS-1 Results For Zidesamtinib In ROS1-Positive Solid Tumors At ASCO 2026

Nuvalent Inc-A (NASDAQ:NUVL) Stock Edges Higher After Q1 2026 Earnings Miss as Investors Focus on Pipeline Milestones

Nuvalent Q1 EPS $(1.39) Misses $(1.36) Estimate

Nuvalent (NUVL) Submits NDA to FDA for Neladalkib in ALK-Positive NSCLC

Nuvalent: A Precision Oncology Platform With Two Near-Term Shots On Goal

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

Assessing Nuvalent (NUVL) Valuation After FDA Review Progress And New ALK ROS1 Trial Data

Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting

Nuvalent To Present Pivotal Data For Neladalkib From Global ALKOVE-1 Phase 1/2 Clinical Study During Oral Presentation At 2026 American Society Of Clinical Oncology Annual Meeting In Chicago

HC Wainwright & Co. Reiterates Buy on Nuvalent, Maintains $155 Price Target

New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026

Nuvalent Reports Zidesamtinib Shows Activity In Pre-Treated ROS1+ Lung Cancer With Strong Brain Penetration Data At AACR 2026

Wedbush Reiterates Outperform on Nuvalent, Maintains $125 Price Target

Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC

Nuvalent Submits NDA To FDA For Neladalkib, Investigational ALK-Selective Inhibitor, In TKI Pre-Treated Advanced ALK-Positive NSCLC.

Wells Fargo Initiates Coverage On Nuvalent with Overweight Rating, Announces Price Target of $116

FDA Review of Zidesamtinib Data Might Change The Case For Investing In Nuvalent (NUVL)